[Chronic kidney disease (CKD) and bone. Vascular calcification in CKD]

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Biochemistry

Background:

• Vascular calcification is a significant contributor to mortality in chronic kidney disease (CKD) patients.
• Hyperphosphatemia is a key inducer of vascular calcification, promoting vascular smooth muscle cells (VSMCs) to adopt an osteochondrogenic phenotype.
• Phosphate regulation is crucial, as both calcium and phosphate load drive vascular calcification.

Purpose of the Study:

• To review the role of hyperphosphatemia in vascular calcification in CKD.
• To discuss the impact of phosphate binders and calcimimetics on vascular calcification.
• To evaluate the potential of therapeutic interventions to reduce cardiovascular events in CKD patients.

Main Methods:

• Literature review of studies on vascular calcification in CKD.
• Analysis of clinical trials on phosphate-lowering therapies.
• Examination of research on calcimimetics in animal models of CKD.

Main Results:

• Lowering serum phosphate with non-calcium-based binders slows vascular calcification progression in ESRD patients.
• Calcimimetics have shown potential in reducing arterial remodeling and calcification in experimental models.
• The clinical translation of these findings to reduced cardiovascular events in humans requires further investigation.

Conclusions:

• Hyperphosphatemia is a critical factor in CKD-associated vascular calcification.
• Therapeutic strategies targeting phosphate levels and calcium load are essential for managing vascular calcification.
• Further research is needed to confirm the efficacy of calcimimetics in reducing cardiovascular events in uremic patients.